Genes of tolerance

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 9, 2004, Pages 897-913

  Akdis, C A ^a   Blaser, K ^a   Akdis, M ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Anergy; G protein coupled receptors; Histamine; Immunoglobulin E; Immunotherapy; T cells; T regulatory cells; Tolerance

Indexed keywords

ALLERGEN; CYCLIC AMP; CYTOKINE; G PROTEIN COUPLED RECEPTOR; HISTAMINE H2 RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

CELL ACTIVATION; CELL DEATH; CLONAL ANERGY; CYTOKINE RELEASE; GENE DISRUPTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN ISOTYPES; IMMUNOTHERAPY; RECEPTORS, HISTAMINE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 4344594695     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00587.x     Document Type: Review

References (203)

1. BILLINGHAM RE, BRENT L, MEDAWAR PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603-606.
2. BURNET F. The Nobel lectures in immunology. The Nobel Prize for physiology or medicine, 1960. Immunologic recognition of self. Scand J Immunol 1991;33:3-13.
3. BURNET FM. The production of antibodies. Melbourne: Macmillan, 1949.
4. PIRQUET V. Das Verhalten der kutaanen Tuberkülin-reaktion wahrend der Masern. Münch Med Wochenschr 1908;34:1297-1300.
5. NOSSAL GJ, PIKE BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci U S A 1980;77:1602-1606.
6. LAMB JR, SKIDMORE BJ, GREEN N, CHILLER JM, FELDMAN M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434-1447.
7. lck and ZAP-70 tyrosine kinase activities. J Immunol 1997;159:53-60.
8. SCHWARTZ RH. T cell anergy. Annu Rev Immunol 2003;21:305-334.
9. DHEIN J, WALCZAK H, BÄUMLER C, DEBATIN KM, KRAMMER PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995;373:438-441.
10. BRUNNER T, MOGIL RJ, LAFACE D, JIN YOO N, MAHBOUBI A, ECHEVERRI F et al. Cell-autonomous Fas (CD95)/ Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-444.
11. AKDIS CA, AKDIS M, TRAUTMANN A, BLASER K. Immune regulation in atopic dermatitis. Curr Opin Immunol 2000;12:641-646.
12. + T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999;163:466-475.
13. ABERNATHY-CARVER KJ, SAMPSON HA, PICKER LJ, LEUNG DYM. Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J Clin Invest 1995;95:913-918.
14. KLUNKER S, TRAUTMANN A, AKDIS M, VERHAGEN J, SCHMID-GRENDELMEIER P, BLASER K et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IP-10, Mig and iTac for T cell chemotaxis towards epidermis in atopic dermatitis. J Immunol 2003;171:1078-1084.
15. LUSTER AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002;14:129-135.
16. GUTIERREZ-RAMOS JC, LLOYD C, KAPSENBERG ML, GONZALO JA, COYLE AJ. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 2000;177:31-42.
17. AKDIS M, TRAUTMANN A, KLUNKER S, DAIGLE I, KÜCÜKSEZER UC, DEGLMANN W et al. T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 2003;17:1026-1035.
18. SIMON H-U, BLASER K. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia. Immunol Today 1995;16:53-55.
19. WHITTAKER L, NIU N, TEMANN UA, STODDARD A, FLAVELL RA, RAY A et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 2002;27:593-602.
20. TRAUTMANN A, AKDIS M, KLEEMANN D, ALTZNAUER F, SIMON HU, GRAEVE T et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000;106:25-35.
21. TRAUTMANN A, SCHMID-GRENDELMEIER P, KRÜGER K, CRAMERI R, AKDIS M, AKKAYA A et al. T cells and eosinophils cooperate in the induction of bronchial epithelial apoptosis in asthma. J Allergy Clin Immunol 2002;109:329-337.
22. TRAUTMANN A, AKDIS M, BROCKER EB, BLASER K, AKDIS CA. New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis. Trends Immunol 2001;22:530-532.
23. TRAUTMANN A, AKDIS M, SCHMID-GRENDELMEIER P, DISCH R, BROCKER EB, BLASER K et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839-846.
24. ROMAGNANT S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-257.
25. MOSMANN TR, SAD S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:142-146.
26. RINCON M, ANGUITA J, NAKAMURA T, FIKRIG E, FLAVELL RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997;185:461-469.
27. CORRY DB. IL-13 in allergy: home at last. Curr Opin Immunol 1999;11:610-614.
28. YSSEL H, GROUX H. Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol 2000;121:10-18.
29. EL BIAZE M, BONIFACE S, KOSCHER V, MAMESSIER E, DUPUY P, MILHE F et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 2003;58:844-853.
30. AKDIS CA, BLASER K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999;13:603-609.
31. AKDIS CA, BLESKEN T, AKDIS M, WÜTHRICH B, BLASER K. Role of IL-10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
32. JUTEL M, AKDIS M, BUDAK F, AEBISCHER-CASAULTA C, WRZYSZCZ M, BLASER K et al. IL-10 and TGF-β cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-1214.
33. CHEN Y, KUCHROO VK, INOBE J, HAFLER DA, WEINER HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
34. low CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589-600.
35. GROUX H, O'GARRA A, BIGLER M, ROULEAU M, ANTONENKO S, DE VRIES JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
36. TAAMS LS, SMITH J, RUSTIN MH, SALMON M, POULTER LW, AKBAR AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001;31:1122-1131.
37. JONULEIT H, SCHMITT E, SCHULER G, KNOP J, ENK AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222.
38. COTTREZ F, HURST SD, COFFMAN RL, GROUX H. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000;165:4848-4853.
39. BOUSQUET J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30(Suppl. 1):2-5.
40. JUTEL M, WATANABE T, KLUNKER S, AKDIS M, THOMET OAR, MALOLEPSZY J et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420-425.
41. HOLGATE ST. Asthma: more than an inflammatory disease. Curr Opin Allergy Clin Immunol 2002;2:27-29.
42. KUSSEBI F, KARAMLOO F, AKDIS M, BLASER K, AKDIS CA. Advances in immunological treatment of allergy. Curr Med Chem 2003;2:297-308.
43. MÜLLER UR, MOSBECH H. Position paper: immunotherapy with hymenoptera venoms. Allergy 1993;48:36-46.
44. BOUSQUET J, LOCKEY R, MALLING HJ, ALVAREZ-CUESTA E, CANONICA GW, CHAPMAN MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401-405.
45. WALKER SM, VARNEY VA, GAGA M, JACOBSON MR, DURHAM SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405-413.
46. VARNEY VA, GAGA M, FREW AJ, ABER VR, KAY AB, DURHAM SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-269.
47. DURHAM SR, WALKER SM, VARGA EM, JACOBSON MR, O'BRIEN F, NOBLE W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.
48. AKDIS CA, AKDIS M, BLESKEN T, WYMANN D, ALKAN SS, MULLER U et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676-1683.
49. DURHAM SR, TILL SJ. Immunological changes associated with allergen immunoherapy. J Allergy Clin Immunol 1998;102:157-164.
50. ROLLAND JM, DOUGLASS J, O'HEHIR RE. Allergen immunotherapy: current and new therapeutic strategies. Exp Opin Invest Drugs 2000;9:515-527.
51. EBNER C. Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 1999;119:1-5.
52. AKDIS CA, BLASER K. Mechanisms of allergen-specific immunotherapy. Allergy 2000;55:522-530.
53. FLICKER S, STEINBERGER P, NORDERHAUG L, SPERR WR, MAJLESI Y, VALENT P et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 2002;32:2156-2162.
54. WETTERWALD A, SKVARIL F, MULLER U, BLASER K. Isotypic and idiotypic characterization of anti-bee venom phospholipase A2 antibodies. Int Arch Allergy Appl Immunol 1985;77:195-197.
55. VAN NEERVEN RJ, WIKBORG T, LUND G, JACOBSEN B, BRINCH-NIELSEN A, ARNVED J et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-2952.
56. ROCKLIN RE, SHEFFER A, GREINEDER DK, MELMON KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213-1219.
57. CRETICOS PS, ADKINSON NF JR, KAGEY-SOBOTKA A, PROUD D, MEIER HL, NACLERIO RM et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985;76:2247-2253.
58. RAK S, LOWHAGEN O, VENGE P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:470-480.
59. OTSUKA H, MEZAWA A, OHNISHI M, OKUBO K, SEKI H, OKUDA M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991;21:115-119.
60. JUTEL M, PICHLER WJ, SKRBIC D, URWYLER A, DAHINDEN C, MULLER UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
61. SECRIST H, CHELEN CJ, WEN Y, MARSHALL JD, UMETSU DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-2130.
62. BELLINGHAUSEN I, METZ G, ENK AH, CHRISTMANN S, KNOP J, SALOGA J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139.
63. 2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998;101:747-754.
64. MARCOTTE GV, BRAUN CM, NORMAN PS, NICODEMUS CF, KAGEY-SOBOTKA A, LICHTENSTEIN LM et al. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998;101:506-513.
65. VON GARNIER C, ASTORI M, KETTNER A, DUFOUR N, HEUSSER C, CORRADIN G et al. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000;30:1638-1645.
66. HASELDEN BM, KAY AB, LARCHE M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885-1894.
67. OLDFIELD WL, LARCHE M, KAY AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47-53.
68. FAITH A, AKDIS CA, AKDIS M, JOSS A, WYMANN D, BLASER K. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J Immunol 1999;162:1836-1842.
69. JANSSEN EM, VAN OOSTERHOUT AJ, VAN RENSEN AJ, VAN EDEN W, NIJKAMP FP, WAUBEN MH. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol 2000;164:580-588.
70. BANERJEE B, KANITPONG K, FINK JN, ZUSSMAN M, SUSSMAN GL, KELLY KJ et al. Unique and shared IgE epitopes of Hev b 1 and Hev b 3 in latex allergy. Mol Immunol 2000;37:789-798.
71. WOODFOLK JA, SUNG SS, BENJAMIN DC, LEE JK, PLATTS-MILLS TA. Distinct human T cell repertoires mediate immediate and delayed-type hypersensitivity to the Trichophyton antigen, Tri r 2. J Immunol 2000;165:4379-4387.
72. GRABIE N, KARIN N. Expansion of neonatal tolerance to self in adult life: II. Tolerance preferentially spreads in an intramolecular manner. Int Immunol 1999;11:907-913.
73. ROLLAND JM, O'HEHIR RE. Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr Opin Immunol 1998;10:640-645.
74. PUNNONEN J, DE WAAL MALEFYT R, VAN VLASSELAER P, GAUCHAT J-F, DE VRIES JE. IL-10 and viral IL-10 prevent IL-4-indiced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280-1289.
75. SONODA E, MATSUMOTO R, HITOSHI Y, ISHII T, SUGIMOTO M, ARAKI S et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 1989;170:1415-1420.
76. WALKER C, VIRCHOW J-C, BRUIJNZEEL PLB, BLASER K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991;146:1829-1835.
77. SCHLEIMER RP, DERSE CP, FRIEDMAN B, GILLIS S, PLAUT M, LICHTENSTEIN LM et al. Regulation of human basophil mediator release by cytokines: I. Interaction with anti-inflammatory steroids. J Immunol 1989;143:1310-1327.
78. TRETER S, LUQMAN M. Antigen-specific T cell tolerance down-regulates mast cell responses in vivo. Cell Immunol 2000;206:116-124.
79. SHIM YK, KIM BS, CHO SH, MIN KU, HONG SJ. Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 2003;33:52-57.
80. MARSHALL JS, LEAL-BERUMEN I, NIELSEN L, GLIBETIC M, JORDANA M. Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 1996;97:1122-1128.
81. SCHANDANE L, ALONSO-VEGA C, WILLEMS F, GERARD C, DELVAUX A, VELU T et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994;152:4368-4374.
82. OHKAWARA Y, LIM KG, GLIBETIC M, NAKANO K, DOLOVICH J, CROITORU K et al. CD40 expression by human peripheral blood eosinophils. J Clin Invest 1996;97:1761-1766.
83. KNECHTLE SJ, HAMAWY MM, HU H, FECHNER JH Jr, CHO CS. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 2001;183:205-213.
84. CHAMBERS CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-223.
85. SCHWARTZ RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996;184:1-8.
86. HOYNE GF, O'HEHIR R, WRAITH DC, THOMAS WR, LAMB JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783-1788.
87. HACZKU A, TAKEDA K, REDAI I, HAMELMANN E, CIESLEWICZ G, JOETHAM A et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Am J Respir Crit Care Med 1999;159:1638-1643.
88. VAN OOSTERHOUT AJ, HOFSTRA CL, SHIELDS R, CHAN B, VAN ARK I, JARDIEU PM et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997;17:386-392.
89. VAN NEERVEN RJ, VAN DE POL MM, VAN DER ZEE JS, STIEKEMA FE, DE BOER M, KAPSENBERG ML. Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. Clin Exp Allergy 1998;28:808-816.
90. GONZALO JA, TIAN J, DELANEY T, CORCORAN J, ROTTMAN JB, LORA J et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2001;2:597-604.
91. DONG C, JUEDES AE, TEMANN UA, SHRESTA S, ALLISON JP, RUDDLE NH et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97-101.
92. AKDIS CA, JOSS A, AKDIS M, FAITH A, BLASER K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000;14:1666-1669.
93. JOSS A, AKDIS M, FAITH A, BLASER K, AKDIS CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000;30:1683-1690.
94. DHAND R, HARA K, HILES I, BAX B, GOUT I, PANAYOTOU G et al. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J 1994;13:511-521.
95. PRASAD KVS, CAI Y-C, RAAB M, DUCKWORTH B, CANTLEY L, SHOELSON SE et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci U S A 1994;91:2834-2838.
96. BOUSSIOTIS VA, TSAI EY, YUNIS EJ, THIM S, DELGADO JC, DASCHER CC et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-1325.
97. TURNER J, GONZALEZ-JUARRERO M, ELLIS DL, BASARABA RJ, KIPNIS A, ORME IM et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002;169:6343-6351.
98. BERREBI D, BRUSCOLI S, COHEN N, FOUSSAT A, MIGLIORATI G, BOUCHET-DELBOS L et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003;101:729-738.
99. GERSHON RK, KONDO K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18:723-737.
100. LEE WY, SEHON AH. Abrogation of reaginic antibodies with modified proteins. Nature 1977;267:618-620.
101. GREEN DR, WEBB DR. Saying the 'S' word in public. Immunol Today 1993;14:523-525.
102. LEVINGS MK, SANGREGORIO R, GALBIATI F, SQUADRONE S, DE WAAL MALEFYT R, RONCAROLO MG. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001;166:5530-5539.
103. BACCHETTA R, SARTIRANA C, LEVINGS MK, BORDIGNON C, NARULA S, RONCAROLO MG. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 2002;32:2237-2245.
104. RONCAROLO MG, BACCHETTA R, BORDIGNON C, NARULA S, LEVINGS MK. Type 1 T regulatory cells. Immunol Rev 2001;182:68-79.
105. BARRAT FJ, CUA DJ, BOONSTRA A, RICHARDS DF, CRAIN C, SAVELKOUL HF et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603-616.
106. NASSER SM, YING S, MENG O, KAY AB, EWAN PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001;31:3704-3713.
107. CHEN Y, INOBE J, KUCHROO VK, BARON JL, JANEWAY CA Jr, WEINER HL. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci U S A 1996;93:388-391.
108. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
109. SHEVACH EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
110. WOOD KJ, SAKAGUCHI S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
111. READ S, POWRIE F. CD4(+) regulatory T cells. Curr Opin Immunol 2001;13:644-649.
112. READ S, MAUZE S, ASSEMAN C, BEAN A, COFFMAN R, POWRIE F. CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 1998;28:3435-3447.
113. WEINER HL. Induction and mechanism of action of transforming growth factor beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-214.
114. KE Y, KAPP JA. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol 1996;156:916-921.
115. WEINER HL. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997;48:341-351.
116. CIUBOTARIU R, COLOVAI AI, PENNESI G, LIU Z, SMITH D, BERLOCCO P et al. Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+ CD28- regulatory T cells. J Immunol 1998;161:5193-5202.
117. SUVAS S, KUMARAGURU U, PACK CD, LEE S, ROUSE BT. CD4+ CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 2003;198:889-901.
118. STROBER S, CHENG L, ZENG D, PALATHUMPAT R, DEJBAKHSH-JONES S, HUIE P et al. Double negative (CD4-CD8- alpha beta+) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev 1996;149:217-230.
119. ZHANG ZX, YANG L, YOUNG KJ, DUTEMPLE B, ZHANG L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 2000;6:782-789.
120. HANNINEN A, HARRISON LC. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 2000;173:109-119.
121. SEO N, TOKURA Y, TAKIGAWA M, EGAWA K. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999;163:242-249.
122. KE Y, PEARCE K, LAKE JP, ZIEGLER HK, KAPP JA. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 1997;158:3610-3618.
123. SEYMOUR BW, GERSHWIN LJ, COFFMAN RL. Aerosol-induced immunoglobulin (Ig)-E unresponsiveness to ovalbumin does not require CD8+ or T cell receptor (TCR)-gamma/delta+ T cells or interferon (IFN)-gamma in a murine model of allergen sensitization. J Exp Med 1998;187:721-731.
124. MAURI C, GRAY D, MUSHTAQ N, LONDEI M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501.
125. REID CD. The biology and clinical applications of dendritic cells. Trans Med 1998;8:77-86.
126. AKBARI O, DEKRUYFF RH, UMETSU DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2:725-731.
127. STEINBRINK K, WOLFL M, JONULEIT H, KNOP J, ENK A. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-4780.
128. MORGANTI-KOSSMANN MC, KOSSMANN T, BRANDES ME, MERGENHAGEN SE, WAHL SM. Autocrine and paracrine regulation of astrocyte function by transforming growth factor-beta. J Neuroimmunol 1992;39:163-173.
129. KAO JY, GONG Y, CHEN CM, ZHENG QD, CHEN JJ. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003;170:3806-3811.
130. RIVAS JM, ULLRICH SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992;149:3865-3871.
131. LIDSTROM C, MATTHIESEN L, BERG G, SHARMA S, ERNERUDH J, EKERFELT C. Cytokine secretion patterns of NK cells and macrophages in early human pregnancy decidua and blood: implications for suppressor macrophages in decidua. Am J Reprod Immunol 2003;50:444-452.
132. DOWDELL KC, CUA DJ, KIRTKMAN E, STOHLMAN SA. NK cells regulate CD4 responses prior to antigen encounter. J Immunol 2003;171:234-239.
133. KITAMURA M, SUTO T, YOKOO T, SHIMIZU F, FINE LG. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996;156:2964-2971.
134. QIN S, COBBOLD SP, POPE H, ELLIOTT J, KIOUSSIS D, DAVIES J et al. 'Infectious' transplantation tolerance. Science 1993;259:974-977.
135. THORNTON AM, SHEVACH EM. CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
136. NAKAMURA K, KITANI A, STROBER W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-644.
137. LEVINGS MK, BACHETTA R, SCHULZ U, RONCAROLO MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Appl Immunol 2002;129:263-276.
138. ITOH M, TAKAHASHI T, SAKAGUCHI N, KUNIYASU Y, SHIMIZU J, OTSUKA F et al. Thymus and autoimmunity: production of CD25+ CD44+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999;162:5317-5326.
139. FOWELL D, MASON D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993;177:627-636.
140. ASANO M, TODA M, SAKAGUCHI N, SAKAGUCHI S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-396.
141. ANNUNZIATO F, COSMI L, LIOTTA F, LAZZERI E, MANETTI R, VANINI V et al. Phenotype, localization, and mechanism of suppression of CD4+ CD25+ human thymocytes. J Exp Med 2002;196:379-387.
142. TAKAHASHI T, TAGAMI T, YAMAZAKI S, UEDE T, SHIMIZU J, SAKAGUCHI N et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-310.
143. READ S, MALMSTROM V, POWRIE F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
144. NISHIMURA H, NOSE M, HIAI H, MINATO N, HONJO T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-151.
145. CARTER L, FOUSER LA, JUSSIF J, FITZ L, DENG B, WOOD CR et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002;32:634-643.
146. MCHUGH RS, WHITTERS MJ, PICCIRILLO CA, YOUNG DA, SHEVACH EM, COLLINS M et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311-323.
147. SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-142.
148. NOCENTINI G, GIUNCHI L, RONCHETTI S, KRAUSZ LT, BARTOLI A, MORACA R et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 1997;94:6216-6221.
149. LEHMANN J, HUEHN J, DE LA ROSA M, MASYZNA F, KRETSCHMER U, KRENN V et al. Expression of the integrin alpha E beta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci U S A 2002;99:13031-13036.
150. LEVINGS MK, SANGREGORIO R, RONCAROLO MG. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-1302.
151. KHATTRI R, COX T, YASAYKO SA, RAMSDELL F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 2003;4:337-342.
152. FONTENOT JD, GAVIN MA, RUDENSKY AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
153. KANANGAT S, BLAIR P, REDDY R, DAHESHIA M, GODFREY V, ROUSE BT et al. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur J Immunol 1996;26:161-165.
154. SCHUBERT LA, JEFFREY E, ZHANG Y, RAMSDELL F, ZIEGLER SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001;276:37672-37679.
155. WILDIN RS, RAMSDELL F, PEAKE J, FARAVELLI F, CASANOVA JL, BUIS TN et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
156. WALKER LS, CHODOS A, EGGENA M, DOOMS H, ABBAS AK. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003;198:249-258.
157. FISSON S, DARRASSE-JEZE G, LITVINOVA E, SEPTIER F, KLATZMANN D, LIBLAU R et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 2003;198:737-746.
158. SUTMULLER RP, VAN DUIVENVOORDE LM, VAN ELSAS A, SCHUMACHER TN, WILDENBERG ME, ALLISON JP et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832.
159. SHIMIZU J, YAMAZAKI S, SAKAGUCHI S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
160. HANSEN G, MCINTIRE JJ, YEUNG VP, BERRY G, THORBECKE GJ, CHEN L et al. CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest 2000;105:61-70.
161. BORISH L, AARONS A, RUMBYRT J, CVIETUSA P, NEGRI J, WENZEL S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996;97:1288-1296.
162. KONING H, NEIJENS HJ, BAERT MR, ORANJE AP, SAVELKOUL HF. T cells subsets and cytokines in allergic and non-allergic children: II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine 1997;9:427-436.
163. PIERKES M, BELLINGHAUSEN I, HULTSCH T, METZ G, KNOP J, SALOGA J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999;103:326-332.
164. TILLIE-LEBLOND I, PUGIN J, MARQUETTE CH, LAMBLIN C, SAULNIER F, BRICHET A et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med 1999;159:487-494.
165. MAKELA MJ, KANEHIRO A, BORISH L, DAKHAMA A, LOADER J, JOETHAM A et al. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc Natl Acad Sci U S A 2000;97:6007-6012.
166. YANG X, WANG S, FAN Y, HAN X. IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthma-like reaction. Eur J Immunol 2000;30:382-391.
167. VIGNOLA AM, CHANEZ P, CHIAPPARA G, MERENDINO A, PACE E, RIZZO A et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997;156:591-599.
168. HELLINGS PW, VANDENBERGHE P, KASRAN A, COOREVITS L, OVERBERGH L, MATHIEU C et al. Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immunol 2002;32:585-594.
169. HANEDA K, SANO K, TAMURA G, SHIROTA H, OHKAWARA Y, SATO T et al. Transforming growth factor-beta secreted from CD4(+) T cells ameliorates antigen-induced eosinophilic inflammation. A novel high-dose tolerance in the trachea. Am J Respir Cell Mol Biol 1999;21:268-274.
170. ALUVIHARE VR, KALLIKOURDIS M, BETZ AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5:266-271.
171. BATTAGLIA A, FERRANDINA G, BUZZONETTI A, MALINCONICO P, LEGGE F, SALUTARI V et al. Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire. Immunology 2003;110:304-312.
172. WOLF AM, WOLF D, STEURER M, GASTL G, GUNSILIUS E, GRUBECK-LOEBENSTAIN B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
173. ANTONY PA, RESTIFO NP. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy. J Immunother 2002;25:202-206.
174. TURNER J, GONZALEZ-JUARRO M, ELLIS DL, BASARABA RJ, KIPNIS A, ORME IM et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002;169:6343-6351.
175. CASAULTA C, SCHONI MH, WEICHEL M, CRAMERI R, JUTEL M, DAIGLE I et al. IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis. Pediatr Res 2003;53:313-319.
176. BELKAID Y, HOFFMANN KF, MENDEZ S, KAMHAWI S, UDEY MC, WYNN TA et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001;194:1497-1506.
177. REDPATH S, GHAZAL P, GASCOIGNE NR. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001;9:86-92.
178. WILSON S, BERGSMA DJ. Orphan G-protein-coupled receptors: novel drug targets for the pharmaceutical industry. Drug Des Discov 2000;17:105-114.
179. JUTEL M, WATANABE T, AKDIS M, BLASER K, AKDIS CA. Immune regulation by histamine. Curr Opin Immunol 2002;14:735-740.
180. AKDIS CA, BLASER K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112:15-22.
181. DEL VALLE J, GANTZ I. Novel insights into histamine H2 receptor biology. Am J Physiol 1997;273:G987-996.
182. LOVENBERG TW, ROLAND BL, WILSON SJ, JIANG X, PYATI J, HUVAR A et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55:1101-1107.
183. DIMITRIADOU V, ROULEAU A, DAM TRUNG TUONG M, NEWLANDS GJ, MILLER HR, LUFFAU G et al. Functional relationship between mast cells and C-sensitive nerve fibres evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci (Lond) 1994;87:151-163.
184. NAKAMURA T, ITADANI H, HIDAKA Y, OHTA M, TANAKA K. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 2000;279:615-620.
185. IDZKO M, LA SALA A, FERRARI D, PANTHER E, HEROUY Y, DICHMANN S et al. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002;109:839-846.
186. GUTZMER R, LANGER K, LISEWSKI M, MOMMERT S, RIECKBORN D, KAPP A et al. Expression and function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002;109:524-531.
187. CARON G, DELNESTE Y, ROELANDTS E, DUEZ C, HERBAULT N, MAGISTRELLI G et al. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J Immunol 2001;166:6000-6006.
188. GANTNER F, SAKAI K, TUSCHE MW, CRUIKSHANK WW, CENTER DM, BACON KB. Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 2002;303:300-307.
189. CARON G, DELNESTE Y, ROELANDTS E, DUEZ C, BONNEFOY JY, PESTEL J et al. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol 2001;167:3682-3686.
190. MAZZONI A, YOUNG HA, SPITZER JH, VISINTIN A, SEGAL DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001;108:1865-1873.
191. VAN DER POUW KRAAN TC, SNIJDERS A, BOEIJE LC, DE GROOT ER, ALEWIJNSE AE, LEURS R et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest 1998;102:1866-1873.
192. VANNIER E, DINARELLO CA. Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Comparison with IL-1 receptor antagonist. J Clin Invest 1993;92:281-287.
193. ELENKOV IJ, WEBSTER E, PAPANICOLAOU DA, FLEISHER TA, CHROUSOS GP, WILDER RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998;161:2586-2593.
194. OSNA N, ELLIOTT K, KHAN MM. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 2001;1:85-96.
195. KUNZMANN S, MANTEL P-Y, WOHLFAHRT JG, AKDIS M, BLASER K, SCHMIDT-WEBER CB. Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J 2003;17:1089-1095.
196. MÜLLER U, HARI Y, BERCHTOLD E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001;107:81-86.
197. JUTEL M, ZAK-NEJMARK T, WRZYYSZCZ M, MALOLEPSZY J. Histamine receptor expression on peripheral blood CD4+ lymphocytes is influenced by ultrarush bee venom immunotherapy. Allergy 1997;52(Suppl. 37): 88.
198. GIFFORD R, SCHMIDKE J. Cimetidine-induced augmentation of human lymphocyte blastogenesis: comparison with levamisole in mitogen stimulation. Surg Forum 1979;30:113-115.
199. TOMITA K, IZUMI K, OKABE S. Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci 2003;93:321-330.
200. BOURINBAIAR AS, JIRATHITIKAL V. Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries. Curr Pharm Des 2003;9:1419-1431.
201. MITSUISHI T, IIDA K, KAWANA S. Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin. Eur J Immunol 2003;13:153-169.
202. BENOVIC J. Novel β2-adrenergic receptor signaling pathways. J Allergy Clin Immunol 2002;110:s229-s235.
203. ROTH M, JOHNSON PR, RUDIGER JJ, KING GG, GE Q, BURGESS JK et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002;360:1293-1299.